Pharmaceutical manufacturers with United States Food and Drug Administration-approved prescription drugs sold in or into Texas with any prescription drugs costing $100 or more for a one-month supply as outlined in Chapter 441, §441.002 (c) are required to submit a manufacturer activity report.

The manufacturer activity report is a list of every drug that has lost patent exclusivity and/or received U.S. FDA approval in the last three calendar years. It also includes the manufacturer’s R&D costs.

Last updated: 08/12/2021

Search by brand/generic name
Manufacturer Change type Change year NDC 11 Trade Name Generic Name R and D cost
ACADIA Pharmaceuticals Inc. A 2016 63090034030 NUPLAZID pimavanserin $240,385,000
ACADIA Pharmaceuticals Inc. A 2016 63090010030 NUPLAZID pimavanserin $240,385,000
Alexion 2020 25682001001 STRENSIQ asfotase alfa $1,010,600,000
Alexion 2020 69583010201 ANDEXXA coagulation factor Xa,inactivated-zhzo (recombinant) $1,010,600,000
Alexion 2020 25682002801 ULTOMIRIS ravulizumab-cwvz $1,010,600,000
Alexion 2020 25682002501 ULTOMIRIS ravulizumab-cwvz $1,010,600,000
Alexion Pharmaceuticals 2020 25682001912 STRENSIQ asfotase alfa $1,010,600,000
Alexion Pharmaceuticals 2020 25682001612 STRENSIQ asfotase alfa $1,010,600,000
Alexion Pharmaceuticals 2020 25682001312 STRENSIQ asfotase alfa $1,010,600,000
Alexion Pharmaceuticals 2020 25682000701 KANUMA sebelipase alfa $1,010,600,000
Alexion Pharmaceuticals 2020 25682000101 SOLIRIS eculizumab $1,010,600,000
Alexion Pharmaceuticals 2020 25682002201 ULTOMIRIS ravulizumab-cwvz $1,010,600,000
Avanir Pharmaceuticals, Inc. 00000000000 Not applicable Not applicable $2,053,177,926
B. Braun Medical Inc. A 2019 00264450005 Plenamine 15% Amino Acids Injection $55,260,000
B. Braun Medical Inc. A 2019 00264937988 Bupivacaine HCl 0.75% in Dextrose 8.25% Injection USP Bupivacaine HCl 0.75% in Dextrose 8.25% Injection USP $55,260,000